Cutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institution
Clicks: 12
ID: 322437
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
3.3
/100
12 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #29 of 178 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 178 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Cutaneous leishmaniasis in the European Mediterranean basin usually presents with discrete self-healing skin lesions. In patients treated with anti-TNF drugs leishmaniasis usually presents with large and persistent cutaneous lesions. With the widespread use of anti-TNF drugs, an increase of severe leishmaniasis in endemic regions and the emergence of cases in non-Mediterranean European countries are to be expected.
| Reference Key |
openalex_W7170161216
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Joaquim Marcoval, Clara Muntaner-Virgili, Nuria Sabé, Júlia Boronat‐Cucarull, Marta Gangonells‐Dols, Álvaro Lagos‐Tapia, Isabel Gil-Castellano |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag322
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.